HOW THE PACE OF CHANGE AFFECTS THE OUTCOMES YOU GET:

Similar documents
A Focus on Health Data Infrastructure, Capacity and Application of Outcomes Data

Patented Medicine Prices Review Board P M P R B GUIDELINES REFORM. 15 th Annual Market Access Summit. Douglas Clark Executive Director PMPRB

December Eucomed HTA Position Paper UK support from ABHI

BIPF Munich. South Africa Enforcement of Pharmaceutical Patents and the New Draft IP Policy

Health Technology Assessment of Medical Devices in Low and Middle Income countries: challenges and opportunities

Why is US Productivity Growth So Slow? Possible Explanations Possible Policy Responses

HTA Position Paper. The International Network of Agencies for Health Technology Assessment (INAHTA) defines HTA as:

The Potential Social and Economic Value of Innovation Procurement

Recent Trend of Generic Medicines Market In Japan

Unified Growth Theory

tepav April2015 N EVALUATION NOTE Science, Technology and Innovation in G20 Countries Economic Policy Research Foundation of Turkey

CRS Report for Congress

How can public and social innovation build a more inclusive economy?

Written Submission for the Pre-Budget Consultations in Advance of the 2019 Budget By: The Danish Life Sciences Forum

Developing Countries in the Globalization of Pharmaceutical Patenting

R&D and innovation activities in companies across Global Value Chains

BOOK REVIEW INTELLECTUAL PROPERTY, PHARMACEUTICALS AND PUBLIC HEALTH: ACCESS TO DRUGS IN DEVELOPING COUNTRIES

Mineral Policy Lessons from Canada and Australia

COMPETITIVNESS, INNOVATION AND GROWTH: THE CASE OF MACEDONIA

Digital Health. Jiban Khuntia, PhD. Assistant Professor Business School University of Colorado Denver

Why behavioural economics is essential for the success of the implementation of a wearable or health app. Behavioural Research Unit

Thomas Jefferson High School for Science and Technology INTRODUCTION TO SCIENCE POLICY Program of Studies

SMA Europe Code of Practice on Relationships with the Pharmaceutical Industry

Submission to the Productivity Commission inquiry into Intellectual Property Arrangements

Scenario Development Process

Government, an Actor in Innovation

Advancing Health and Prosperity. A Brief to the Advisory Panel on Healthcare Innovation

The Health Information Future: Evolution and/or Intelligent Design?

Pharmaceutical Promotion in Medical (and Pharmacist) Training in the Netherlands: Readiness for Curriculum Change

17.181/ SUSTAINABLE DEVELOPMENT Theory and Policy

Dynamics of National Systems of Innovation in Developing Countries and Transition Economies. Jean-Luc Bernard UNIDO Representative in Iran

RIS3 from Strategic Orientations towards Policy Implementation: The Challenges Claire NAUWELAERS Independent expert in STI policy

Why is US Productivity Growth So Slow? Possible Explanations Possible Policy Responses

Killing One Bird with Two Stones: Pharmaceutical Patents in the Wake of Pfizer v Apotex and KSR v Teleflex

Horizon Scanning. Why & how to launch it in Lithuania? Prof. Dr. Rafael Popper

Chapter 8. Technology and Growth

Host Partners Foundation Partners Stream Partners. Melbourne August 2014

Submission to the Department of Industry, Innovation and Science on the Productivity Commission s Final Report on Intellectual Property Arrangements

PRIMARY CARE CO-COMMISSIONING

Globalizing IPR Protection: How Important Might RTAs Be?

UNFPA/WCARO Census: 2010 to 2020

Decision regarding PHARMAC s Implementation of Trans-Pacific Partnership (TPP) provisions and other Amendments to Application Processes

An Essential Health and Biomedical R&D Treaty

Parenteral Nutrition Down Under Inc. (PNDU) Working with Pharmaceutical Companies Policy (Policy)

Energy Trade and Transportation: Conscious Parallelism

Parliamentary Research Branch PATENT DEDICATION AND THE PATENTED MEDICINE PRICES REVIEW BOARD. Margaret Smith Law and Government Division

HOW TO BUILD AN INNOVATION ECOSYSTEM?

A stronger system to protect the health and safety of Canadians. Exploring the Future of the Food Regulatory Framework Under the Food and Drugs Act

Book Note: Memoirs And Reflections, by Roy McMurtry

The Investigation of Bio-medical Science and Technology Innovation Service Platform in Guangzhou

The Role of Patients in Transitions of Care

Role of Knowledge Economics as a Driving Force in Global World

ICAD Public Engagement Strategy

The TRIPS Agreement and Patentability Criteria

Health Technology Assessment: What are the key challenges to assess medical devices? Rosanna Tarricone, PhD Director CERGAS Scientific Director EHTI

MSMES: OPPORTUNITIES AND CHALLENGES FOR THE SDG AGENDA

OECD Innovation Strategy: Key Findings

POLITICAL MEXICO S BACKGROUND. Federal (president, chamber of deputies, senate), and local. elections in 94% of the country. Nothing is yet decided

MedTech Europe position on future EU cooperation on Health Technology Assessment (21 March 2017)

SAUDI ARABIAN STANDARDS ORGANIZATION (SASO) TECHNICAL DIRECTIVE PART ONE: STANDARDIZATION AND RELATED ACTIVITIES GENERAL VOCABULARY

Draft Plan of Action Chair's Text Status 3 May 2008

Learning from Evaluation when Context Matters

Model Based Design Of Medical Devices

Policy packaging or policy patching? The development of complex policy mixes

NCRIS Capability 5.7: Population Health and Clinical Data Linkage

Managing Conflict of Interest

How can value be measured and assessed?

August 17, The Testimony of Christopher P. Molineaux President & CEO Pennsylvania Bio

Report of Visit to Agency ANI Portugal. Lisbon, 2 May 2016

Overview of Health Technology Assessment (HTA) from Asia Pacific Perspective

EDQM COUNCIL OF EUROPE CONFERENCE CERTIFICATION PROCEDURE : 20 YEARS OF EXPERIENCE March EDQM, Strasbourg, France ABSTRACTS

SURGERY STRATEGIC CLINICAL NETWORK EVIDENCE DECISION SUPPORT PROGRAM. New ideas & Improvements

Twenty-Thirty Health care Scenarios - exploring potential changes in health care in England over the next 20 years

Chee-Ruey Hsieh EDUCATION PROFESIONAL EMPLOYMENT RECORD MAJOR RESEARCH FIELD

Norway Resource management and nation building

The prospective contribution and the global and integrated approach to pharmaceutical industry s new challenges.

ABHI Response to the Kennedy short study on Valuing Innovation

Cross-Border R&D in China Understanding the Regulatory Challenges

special roundtable Andrew D. Marble Kenneth Lieberthal Emily O. Goldman Robert Sutter Ezra F. Vogel Celeste A. Wallander

Establishing a Development Agenda for the World Intellectual Property Organization

Virtual Mentor American Medical Association Journal of Ethics December 2006, Volume 8, Number 12:

Enforcement of Intellectual Property Rights Frequently Asked Questions

A differentiated approach to mission-oriented innovation policy: Contextualizing societal challenges in a problem-solution space

executives are often viewed to better understand the merits of scientific over commercial solutions.

Research and Development Spending

Canada-Italy Innovation Award Call for Proposals

HealthTech: What does it mean for compliance?

Health Technology Strategy 1.0. June 2004

The European Semiconductor industry: 2005 Competitiveness Report. DG Enterprise

Chapter 1 Introduction

Identifying key enablers of ICT-enabled social innovation in support of social policy reforms in the EU

Chapter 22. Technological Forecasting

Globalisation increasingly affects how companies in OECD countries

Social Sciences and Humanities in the Framework Programmes

Economic Clusters Efficiency Mathematical Evaluation

Medical Research Council

IPRs and Public Health: Lessons Learned Current Challenges The Way Forward

Planetary Economics: international dimensions

Innovation in HTA: What is the additional value?

Designing an ethical complement to the patent regime for pharmaceutical innovation. Pharma-Innovation Patent-2

Transcription:

HOW THE PACE OF CHANGE AFFECTS THE OUTCOMES YOU GET: T H E C A S E O F P H A R M A C E U T I C A L I N S U R A N C E I N C A N A D A, T H E U K A N D A U S T R A L I A CHEPA Seminar, April 2011 Katherine Boothe, PhD boothek@mcmaster.ca Department of Political Science, McMaster University

THE PUZZLE Canada: only country with a broad public health system that excludes drugs

THE PUZZLE Canada: only country with a broad public health system that excludes drugs Puzzling in light of Similar welfare states and own public hospital and medical insurance Early Canadian plans for health policy Federal Green Book proposals in 1945 include pharmaceuticals as a later stage

THE PUZZLE Canada: only country with a broad public health system that excludes drugs Why? Accepted wisdom based on timing of technological change

THE PUZZLE Canada: only country with a broad public health system that excludes drugs Why? Accepted wisdom based on timing of technological change In 1960s (when Medicare was implemented and post-therapeutic revolution), drugs were too expensive

THE PUZZLE Canada: only country with a broad public health system that excludes drugs Why? Accepted wisdom based on timing of technological change In 1960s (when Medicare was implemented and post-therapeutic revolution), drugs were too expensive Evidence from Canada: cost concerns present earlier; drug programs also considered later

GENERAL RESEARCH PROBLEM Changes to health programs proposed more often than adopted Why are they implemented in some cases and not in others? Why do certain types of change become more difficult over time?

GENERAL RESEARCH PROBLEM How does the approach to policy development affect outcomes?

GENERAL RESEARCH PROBLEM How does the approach to policy development affect outcomes? Distinguish between radical and incremental approaches Radical: centralized institutions, principled ideas, electoral incentives Incremental: these conditions absent, change still possible but outcomes are different

GENERAL RESEARCH PROBLEM How does the approach to policy development affect outcomes? Distinguish between radical and incremental approaches Over time, barriers increase: adopting an additional service is more difficult later in process New mechanism based on reciprocal relationship between elite ideas and public expectations

OVERVIEW Empirical puzzle Cases and outcomes Analytical problems Why does the pace of change vary? How does the pace of change affect outcomes? Main findings Contributions and future research

CASES AND OUTCOMES Liberal welfare states: Canada, the UK and Australia Similar welfare moment at the end of WWII Pace of policy development different Outcomes (comprehensiveness of health system) different

CASES AND OUTCOMES UK: quick, radical change; all health services simultaneously; comprehensive program

CASES AND OUTCOMES UK: quick, radical change; all health services simultaneously; comprehensive program Canada and Australia: slower, incremental change; one service at a time; no comprehensive program Australia: Pharmaceutical Benefits Scheme 1950, no hospital or medical insurance until 1975-1984 Canada: Hospital and medical insurance 1957-1966. no pharmaceutical insurance

OVERVIEW Empirical puzzle Cases and outcomes Analytical problems Why does the pace of change vary? How does the pace of change affect outcomes? Main findings Contributions and future research

1. PACE OF CHANGE: THEORY Radical approach when there is: Centralized institutional authority Principled elite ideas Electoral incentives These conditions present in the UK but not Canada or Australia

1. PACE OF CHANGE: FINDINGS UK: Institutions: Unitary system, centralized parliamentary government Ideas: New Labour majority government and Beveridge Report; consensus re: comprehensive service Electoral motivation: Policy popular and salient; 88% of voters in favour

1. PACE OF CHANGE: FINDINGS Canada Institutions: Fragmentation key; focus on provincial flexibility 1955: PM St. Laurent wished to avoids federal interference in matters which are essentially of provincial concern. Ideas: PMs Mackenzie King and St. Laurent deeply skeptical about public health insurance

1. PACE OF CHANGE: FINDINGS Australia Ideas: 1943, PM John Curtin notes it is impracticable in war-time to devise and introduce a comprehensive scheme for all these [health] services

1. PACE OF CHANGE: FINDINGS Australia Ideas: 1943, PM John Curtin notes it is impracticable in war-time to devise and introduce a comprehensive scheme for all these [health] services Electoral motivation: Neither Canadian nor Australian politicians prodded by public opinion on health Health policies generally popular but low salience

1. PACE OF CHANGE: FINDINGS UK adopted all services, including prescription services, with the NHS in 1946

1. PACE OF CHANGE: FINDINGS UK adopted all services, including prescription services, with the NHS in 1946 Canada and Australia took incremental approaches Similar language re: proceeding in stages or steps Process quickly stalled Predictable: approach to policy development influences the creation of barriers to policy change

OVERVIEW Empirical puzzle Cases and outcomes Analytical problems Why does the pace of change vary? How does the pace of change affect outcomes? Main findings Contributions and future research

2. BARRIERS TO CHANGE: THEORY Why do incremental processes stall; how do barriers to policy change arise?

2. BARRIERS TO CHANGE: THEORY Why do incremental processes stall; how do barriers to policy change arise? Path dependence literature: policies tend to be self-reinforcing

2. BARRIERS TO CHANGE: THEORY Why do incremental processes stall; how do barriers to policy change arise? Path dependence literature: policies tend to be self-reinforcing Alternative institutional arrangements in the absence of government programs Private actors make investments and create networks that are difficult to displace

2. BARRIERS TO CHANGE: THEORY These factors important but cannot fully explain Canadian pharmaceutical policy

2. BARRIERS TO CHANGE: THEORY These factors important but cannot fully explain Canadian pharmaceutical policy New mechanism based on adaptive expectations

2. BARRIERS TO CHANGE: THEORY These factors important but cannot explain Canadian pharmaceutical policy New mechanism based on adaptive expectations Strong effect when consider the reciprocal relationship between elite ideas and public expectations

2. BARRIERS TO CHANGE: THEORY Strong effect when consider the reciprocal relationship between elite ideas and public expectations Choice of policy approach: principled elite ideas and electoral motivations complementary Same dynamic works in negative way to stall incremental process

2. BARRIERS TO CHANGE: THEORY Choice of policy approach: principled elite ideas and electoral motivations complementary Same dynamic works in negative way to stall incremental process Incremental approach: no principled ideas, early public promises for services are vague

2. BARRIERS TO CHANGE: THEORY Incremental approach: no principled ideas, early public promises for services are vague Public does not develop expectations re: additional services Politicians ideas become more restricted Lack of elite ideas and public expectations reinforce one another over time to restrict the policy agenda

2. BARRIERS TO CHANGE: FINDINGS Canada Pharmaceuticals low priority by 1950: all experience to date indicates that it is almost impossible to control the cost in such services Idea was persistent and stifled further discussion

2. BARRIERS TO CHANGE: FINDINGS Canada Late 1950s: High drug prices were on the agenda 1966: Federal government starts separate program to curb prices through patent law

2. BARRIERS TO CHANGE: FINDINGS Canada Late 1950s: High drug prices were on the agenda 1966: Federal government starts separate program to curb prices through patent law Consensus about problem of pharmaceuticals: only about prices and patents

2. BARRIERS TO CHANGE: FINDINGS Canada 1966: Federal government starts separate program to curb prices through patent law Consensus about problem of pharmaceuticals: only about prices and patents 1972: DHW proposes national pharmacare but politicians ideas are limited by previous consensus on drugs

2. BARRIERS TO CHANGE: FINDINGS Canada 1972: DHW proposes national pharmacare but politicians ideas are limited by previous consensus on drugs Lack of electoral pressure: Canadians have no experience with drug insurance and no public discussion of issue Barriers to the late adoption of an additional service too high

2. BARRIERS TO CHANGE: FINDINGS Australia First priority service was pharmaceuticals: an option that will not involve any significant additional drain on professional man power Additional services received limited attention

2. BARRIERS TO CHANGE: FINDINGS Australia First priority service was pharmaceuticals: an option that will not involve any significant additional drain on professional man power Additional services received limited attention 1949: new government elected, opposes broad public health insurance

2. BARRIERS TO CHANGE: FINDINGS Australia Find reciprocal relationship between elite ideas and public expectations can affect outcomes quickly

2. BARRIERS TO CHANGE: FINDINGS Australia Find reciprocal relationship between elite ideas and public expectations can affect outcomes quickly Legislation passed by Labour government in 1944 but BMA refused to cooperate Liberal government chose to implement in 1949 despite general opposition to government insurance or benefits

2. BARRIERS TO CHANGE: FINDINGS Australia Early 1946: Constitutional challenge, PBS legislation struck down Late 1946: Constitutional referendum and amendment to give federal government power over pharmaceutical benefits 1947: New legislation, still not implemented 1949: Second constitutional challenge

2. BARRIERS TO CHANGE: FINDINGS Australia High profile conflict affected voters expectations for free medicines Change in expectations fed back into electoral motivations Even before policy implementation, reciprocal relationship between ideas and expectations allowed for unexpected outcome

SUMMARY OF FINDINGS Why doesn t Canada have pharmacare? Institutional, ideational and electoral factors produced incremental approach to health policy

SUMMARY OF FINDINGS Why doesn t Canada have pharmacare? Institutional, ideational and electoral factors produced incremental approach to health policy Pharmaceuticals low place on the policy agenda was self-reinforcing because of restriction of elite ideas and therefore public expectations over time

SUMMARY OF FINDINGS Why doesn t Canada have pharmacare? Institutional, ideational and electoral factors produced incremental approach to health policy Pharmaceuticals low place on the policy agenda was self-reinforcing because of restriction of elite ideas and therefore public expectations over time Similar dynamic helps explain why Australia only had pharmaceutical benefits for so long

SUMMARY OF FINDINGS Relationship between elite ideas and public expectations also suggests how barriers are (sometimes) overcome Small changes take on characteristics of radical reforms as barriers to change increase Require centralized institutional authority, principled ideas and electoral motivation to reach agenda and overcome barriers

OVERVIEW Empirical puzzle Cases and outcomes Analytical problems Why does the pace of change vary? How does the pace of change affect outcomes? Main findings Contributions and future research

CONTRIBUTIONS Approach to policy development matters Even if they start with similar goals, incremental versus radical approach will produce different outcomes Dynamics of different approaches help conceptualize the barriers to policy change we expect to see

CONTRIBUTIONS Reciprocal relationship between elite ideas and public expectations help explain policy stability and change Elites tend to develop blind spots about a policy over time This also affects the way the public thinks about the policy area

FUTURE RESEARCH What does this mean for current health policy?

FUTURE RESEARCH What does this mean for current health policy? Implications for the adoption of additional services Predict will require three conditions for radical change Preliminary evidence to support: Australian hospital and medical insurance 1975-1984

FUTURE RESEARCH How does the initial pace of change influence opportunities to reform existing services?

FUTURE RESEARCH How does the initial pace of change influence opportunities to reform services? Motivated by convergence and divergence of pharmaceutical programs in Canada, the UK and Australia Canada is still an outlier, but coverage has expanded through provincial programs UK and Australia applied different types of solutions to similar cost pressures

FUTURE RESEARCH How does the initial pace of change influence opportunities to reform services? Expect conditions that produce a radical pace of change initially would also make services more difficult to retrench Preliminary evidence to support: attempts to introduce patient charges for prescriptions in the UK and Australia

THANK YOU!

CASES: FEDERALISM Institutional fragmentation should lead to a slower pace of change and radical outcomes Does it provide a full explanation? Centralized authority: what a government can do but not what it does Also consider role of ideas and electoral motivations to explain process of policy development

Year 2008 Dollars Per Capita REAL SPENDING PER CAPITA: 1975 $1,500 $1,250 $1,000 $750 $500 $250 Public Private $0 Hospitals Physicians Other Institutions Other Prof. Medicines Capital Public Health Administration Source: Morgan 2009, based in CIHI data

Year 2008 Dollars Per Capita REAL SPENDING PER CAPITA: 2008 $1,500 $1,250 $1,000 $750 $500 $250 Public Private $0 Hospitals Physicians Other Institutions Other Prof. Medicines Capital Public Health Administration Source: Morgan 2009, based in CIHI data

PRESCRIBED DRUG EXPENDITURE BY PROVINCE: 2008 80 70 60 50 40 30 % Public 20 10 0 Source: based on CIHI 2009 data

AUSTRALIA S SECOND STEP Medibank first introduced 1975 After 25 years of no health policy development, this was a radical step, requiring: Centralized authority: Commonwealth government financially if not constitutionally supreme Principled ideas: new Whitlam Labor government and plan by Melbourne Uni economists Electoral motivations: Increasing dissatisfaction with private plans and popularity of new proposals